News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
The Rising Research Profile of 23andMe
Catherine Offord | Nov 30, 2017
An exploration of the genetics of earlobe attachment is just the latest collaborative research project to come out of the personal genetic testing company.
Pfizer to Buy Medivation for $14 Billion
Bob Grant | Aug 22, 2016
The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.
NYU Halts Studies, Suspends Investigator
Bob Grant | Jun 28, 2016
Experiments conducted at the New York University School of Medicine violated several research standards, according to US Food and Drug Administration investigators.
Pfizer Scoops Anacor for $5.3 Billion
Bob Grant | May 18, 2016
The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.
Pfizer-Allergan Merger Scrapped
Bob Grant | Apr 7, 2016
A move by the US federal government to close tax loopholes that encourage “tax inversions” likely spooked the companies out of the multibillion dollar deal.
Pfizer and Allergan to Merge
Bob Grant | Nov 23, 2015
The two drugmakers will join forces in a $160 billion deal—if it’s given the regulatory green light.
Pfizer to Acquire Hospira
Bob Grant | Feb 5, 2015
The pharmaceutical giant is purchasing the injectable drugmaker for about $15 billion.
Pfizer Scientist Dies
Beth Marie Mole | Jan 25, 2013
Genetics researcher and senior vice president of the pharmaceutical giant, David Cox, has passed away unexpectedly at age 66.
First Drug from GM Plant Approved
Megan Scudellari | May 4, 2012
A human enzyme grown in carrot cells will treat patients with Gaucher disease.